Prognostic values of lung volumes in cohorts of persons with various degree of cardiovascular risk

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

According to the data of modern epidemiological studies, a stable tendency towards an increase in the prevalence of traditional cardiovascular risk (CVR) factors in young persons is forming, the significance of which in the development of chronic non-communicable diseases in this cohort of patients is complicated by the lack of validated prognostic models. Scientific research works indicate the possibility of using lung volumes as an integral prognostic marker in various age cohorts of conditionally healthy patients.

The aim: to study prognostic lung volume values in different cohorts of individuals depending on age and degree of cardiovascular risk according to the SCORE2 and Framingham-30 scales.

Material and methods. 145 individuals aged 20 to 60 years were included in the study. CVR was calculated using the SCORE2 and Framingham-30 scales. The participants underwent spirometry without a bronchodilator test, with estimation of the volume of formed exhalation in 1 second (FEV1), forced vital capacity (FVC) and their ratio. Correlations between the values of these lung volumes and the category of cardiovascular risk were assessed.

Results. According to SCORE2 scale, 3.6% of respondents belonged to the low-risk category, while the majority of participants belonged to the moderate or high risk categories. The SCORE2 CVR category had no significant associations with lung volume parameters, with the exception of the lower limit of normal (LLN) of FEV1/FVC (p < 0.001). As expected, a 1% increase in SCORE2 was accompanied by a 1.4% decrease in the LLN of the FEV1/FVC ratio. When analyzing the risk by Framingham-30 scale with the addition of lipid panel parameters and including individuals aged 20 years and over, a decrease in lung volumes was most significantly associated with high CVR (p < 0.05). An increase in the Framingham-30 risk (with lipid panel data) correlated with a 0.07% decrease in the LLN of FEV1/FVC (ρ = -0.8; p < 0.001).

Conclusion. Correlations between lung function parameters and 30-year CVR were found. Combining the Framingham-30 scale and lung volumes is a promising direction for further study of these correlations and creation of an expanded algorithm for risk assessment in younger individuals.

全文:

受限制的访问

作者简介

Vera Nevzorova

Pacific State Medical University of the Ministry of Healthcare of Russia

编辑信件的主要联系方式.
Email: nevzorova@inbox.ru
ORCID iD: 0000-0002-0117-0349
SPIN 代码: 5232-0247
Scopus 作者 ID: 6603425593

MD, Dr. Sci. (Medicine), professor, Director of the Institute of therapy and instrumental diagnostics

俄罗斯联邦, Vladivostok

Lyudmila Priseko

Pacific State Medical University of the Ministry of Healthcare of Russia

Email: ludmilka.95.95@yandex.ru
ORCID iD: 0000-0002-3946-2064
SPIN 代码: 3393-2418
Scopus 作者 ID: 57216433877

MD, lecturer of the Institute of therapy and instrumental diagnostics

俄罗斯联邦, Vladivostok

Anna Menovshchikova

Pacific State Medical University of the Ministry of Healthcare of Russia

Email: menovshhikovaan@mail.ru
ORCID iD: 0000-0002-2375-6973

clinical resident in specialty 31.08.36 “Cardiology”

俄罗斯联邦, Vladivostok

Ekaterina Shumakova

Pacific State Medical University of the Ministry of Healthcare of Russia

Email: rinkamakova06@mail.ru
ORCID iD: 0009-0008-8780-957X

6th year student in specialty 31.05.01 “General medicine”

俄罗斯联邦, Vladivostok

参考

  1. Долбин С.С., Адашева Т.В., Саморукова Е.И. с соавт. Стратификация сердечно-сосудистого риска у больных хронической обструктивной болезнью легких. Терапия. 2020; 6(5): 69–77. [Dolbin S.S., Adasheva T.V., Samorukova E.I. et al. Stratification of cardiovascular risk in patients with chronic obstructive pulmonary disease. Terapiya = Therapy. 2020; 6(5): 69–77 (In Russ.)]. https://doi.org/10.18565/therapy.2020.5.69-77. EDN: EZTSXX.
  2. Cheng Y.-J., Chen Z.-G., Li Z.-Y. et al. Longitudinal change in lung function and subsequent risks of cardiovascular events: Evidence from four prospective cohort studies. BMC Med. 2021; 19(1): 153. https://doi.org/10.1186/s12916-021-02023-3. PMID: 34210292. PMCID: PMC8252272.
  3. Agusti A., Faner R. Lung function trajectories in health and disease. Lancet Respir Med. 2019; 7(4): 358–64. https://doi.org/10.1016/S2213-2600(18)30529-0. PMID: 30765254.
  4. Agusti A., Fabbri L.M., Baraldi E. et al. Spirometry: A practical lifespan predictor of global health and chronic respiratory and non-respiratory diseases. Eur J Intern Med. 2021; 89: 3–9. https://doi.org/10.1016/j.ejim.2021.04.027. PMID: 34016514.
  5. Ching S.-M., Chia Y.-C., Lentjes M.A.H. et al. FEV1 and total cardiovascular mortality and morbidity over an 18 years follow-up population-based prospective EPIC-NORFOLK Study. BMC Public Health. 2019; 19(1): 501. https://doi.org/10.1186/s12889-019-6818-x. PMID: 31053065. PMCID: PMC6500069.
  6. Granell R., Haider S., Deliu M. et al.; STELAR/UNICORN investigators. Lung function trajectories from school age to adulthood and their relationship with markers of cardiovascular disease risk. Thorax. 2024; 79(8): 770–77. https://doi.org/10.1136/thorax-2023-220485. PMID: 38697843. PMCID: PMC11287578.
  7. Zaigham S., Eriksson K.-F., Wollmer P., Engström G. Low lung function, sudden cardiac death and non-fatal coronary events in the general population. BMJ Open Respir Res. 2021; 8(1): e001043. https://doi.org/10.1136/bmjresp-2021-001043. PMID: 34531228. PMCID: PMC8449980.
  8. Chipayo-Gonzales D., Ramakrishna H., Nuñez-Gil I.J. Score2: A new updated algorithm to predict cardiovascular disease risk in Europe. J Сardiothorac Vasc Anesth. 2022; 36(1): 18–21. https://doi.org/10.1053/j.jvca.2021.09.033. PMID: 34686439.
  9. Веретюк В.В., Цыганкова О.В., Аметов А.С. Оценка сердечно-сосудистого риска у молодых мужчин. Доктор.Ру. 2023; 22(4): 7–17. [Veretyuk V.V., Tsygankova O.V., Ametov A.S. Evaluation of a cardiovascular risk in young men. Doctor.Ru. 2023; 22(4): 7–17 (In Russ.)]. https://doi.org/10.31550/1727-2378-2023-22-4-7-17. EDN: XGTAKO.
  10. Каменева М.Ю., Черняк А.В., Айсанов З.Р. с соавт. Спирометрия: методическое руководство по проведению исследования и интерпретации результатов. Пульмонология. 2023; 33(3): 307–340. [Kameneva M.Yu., Chernyak A.V., Aisanov Z.R. et al. Spirometry: National guidelines for the testing and interpretation of results. Pulmonologiya = Pulmonology. 2023; 33(3): 307–340 (In Russ.)]. https://doi.org/10.18093/08690189-2023-33-3-307-340. EDN: DHQGAM.
  11. Costanzo S., Magnacca S., Bonaccio M. et al.; Moli-sani Study Investigators. Reduced pulmonary function, low-grade inflammation and increased risk of total and cardiovascular mortality in a general adult population: Prospective results from the Moli-sani study. Respir Med. 2021; 184: 106441. https://doi.org/10.1016/j.rmed.2021.106441. PMID: 34004499.
  12. Janson C., Potts J., Malinovschi A. et al.; BOLD Collaborative Research Group. Lung function and onset of cardiometabolic diseases in the longitudinal Burden of Obstructive Lung Disease study. BMJ Open Respir Res. 2025; 12(1): e002442. https://doi.org/10.1136/bmjresp-2024-002442. PMID: 39832891. PMCID: PMC11751964.
  13. Sarycheva T., Čapková N., Pająk A. et al. Can spirometry improve the performance of cardiovascular risk model in high-risk Eastern European countries? Front Cardiovasc Med. 2023; 10: 1228807. https://doi.org/10.3389/fcvm.2023.1228807. PMID: 37711557. PMCID: PMC10497938.

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Graph of the regression function characterizing the dependence of cardiovascular risk indicators according to the SCORE2 scale on the lower limit of the normal modified Tiffeneau index

下载 (113KB)
索引源数据
3. Fig. 2. Values ​​of forced expiratory volume in 1 second (FEV1, l) depending on the category of overall and severe cardiovascular risk, calculated according to the F30-lip scale (relationship between FEV, and low, moderate and high overall and severe risks, p = 0.02) and F30-bmi (relationship between FEV, and low, moderate and high overall and severe risks, p = 0.03)

下载 (110KB)
索引源数据
4. Fig. 3. Values ​​of the ratio of forced expiratory volume in 1 second (FEV1) and forced vital capacity of the lungs (%) depending on the category of general and severe cardiovascular risk, calculated using the F30-lip and F30-bmi scales (relationship between FEV1 and low, moderate and high general and severe risks, p<0.001)

下载 (115KB)
索引源数据
5. Fig. 4. Graph of the regression function characterizing the dependence of the overall risk on the F30-lip scale on the lower limit of the modified Tiffeneau index

下载 (135KB)
索引源数据

版权所有 © Bionika Media, 2025